NCT01486875View on ClinicalTrials.gov

Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes

CompletedOBSERVATIONAL

Enrollment

1,155

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 30

Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily

Trial Locations (1)

221 85

Novo Nordisk Investigational Site, Lund

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY